T1	Participants 111 136	granulocytopenic patients
T2	Participants 440 510	Patients were stratified into two groups: favorable-prognosis, group 1
T3	Participants 552 585	or unfavorable-prognosis, group 2
T4	Participants 762 803	group 1 (55 of 62 patients or 89 per cent
T5	Participants 813 853	group 2 (42 of 64 patients, 66 per cent)
